Compare LVRO & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LVRO | CNTB |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.5M | 128.6M |
| IPO Year | N/A | 2021 |
| Metric | LVRO | CNTB |
|---|---|---|
| Price | $0.99 | $2.51 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $1.88 | ★ $8.50 |
| AVG Volume (30 Days) | 86.8K | ★ 94.0K |
| Earning Date | 03-09-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,346,609,973.00 | $762,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $11.45 | $24,739.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.19 | $0.51 |
| 52 Week High | $5.40 | $3.28 |
| Indicator | LVRO | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 47.85 | 54.22 |
| Support Level | $1.04 | $2.23 |
| Resistance Level | $1.18 | $2.70 |
| Average True Range (ATR) | 0.08 | 0.24 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 13.32 | 70.18 |
Lavoro Ltd operates in the agricultural inputs retail market, with operations spread across Brazil and Colombia, and an emergent agricultural input trading company in Uruguay. The reportable segments of the company include the Brazil Ag Retail, which comprises companies dedicated to the distribution of agricultural inputs such as crop protection, seeds, fertilizers, and specialty products, in Brazil; Latam Ag Retail, which includes companies dedicated to the distribution of agricultural inputs outside Brazil (predominantly in Colombia); and the Crop Care. A substantial part of the company's overall revenue is generated from its Brazil Ag Retail segment.
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.